explore -WSS

explore

author：knowledge 2025-10-02 17:26:56 - browse：136

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： The creative science of coining drug names

explore

WSS

Medicare Advantage proposed rates disappoint insurers

Readout LOUD podcast: How biotech is using artificial intelligence

Most antidepressants don't work on kids, teens, study finds

To avoid data mishandling cases, universities eye AI and other tools

Industry veterans launch new biotech VC with $310M

Can gargling with Listerine treat gonorrhea of the mouth?

hotspot

explore

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Private equity deals in Medicare Advantage declines

Wildfire smoke exposes gaps in outdoor worker protections

Senators start work on Medicare physician payment reform

Affirmative action in medical school literally saved lives

Empower primary care with adequate payments and technology

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Moonlake's readout produced a cash windfall. Risks remain

PBM executives asked to testify by House panel

hotspot

'Revelatory' study finds a smoking impact that remains after quitting

For Medicare Advantage, Democrats want stronger protections around AI

Key House Republican on health care plans exit from Congress

Biden report: The neurospychology of memory and aging

Industry veterans launch new biotech VC with $310M

Private equity deals in Medicare Advantage declines

focus

hotspot

explore

hotspot